|
End-of-day quote
Shanghai S.E.
2026-09-01
|
5-day change | 1st Jan Change | ||
| 18.41 CNY | -0.22% |
|
0.00% | +4.48% |
| 08-24 | DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-24 | Dashenlin Pharma's Q1 Profit Rises 11% | MT |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 5.1% | 5.65% | 14.09x | 2.68x | 0.6x | 4.64x | 7.63x | 3.12B | ||
| -.--% | -.--% | 16.69x | 1.51x | 0.67x | 10.01x | 10.89x | 14.85B | ||
| 2.2% | 2.53% | 16.9x | 1.74x | 0.76x | 7.93x | 9.95x | 6.43B | ||
| 1.09% | 1.35% | 20.6x | 2.32x | 0.78x | 13.13x | 13.39x | 6.37B | ||
| 3.05% | 3.29% | 14.62x | 2.18x | 0.9x | 6.22x | 8.44x | 4.13B | ||
| 5.59% | 6.14% | 14.38x | 4.36x | 1.23x | 7.56x | 14.17x | 3.2B | ||
| 4.69% | 5.14% | 13.67x | 6.19x | 0.82x | 6.16x | 8.58x | 2.88B | ||
| 2.03% | 2.46% | 20.28x | 3.55x | 0.59x | 7.57x | 12.39x | 1.51B | ||
| 0.02% | -.--% | -128.68x | 2.67x | 0.44x | 15.85x | 68.49x | 1.49B | ||
| 3.35% | 4.57% | 13.78x | 0.86x | 0.29x | 2.61x | 6.66x | 952M | ||
| 5.93% | 5.94% | 17.96x | 2.17x | 0.82x | 7.51x | 17.72x | 870M | ||
| 1.29% | 1.86% | 27.82x | 7.59x | 1.01x | 13.72x | 21.27x | 845M | ||
| 0.37% | 0.36% | 14.04x | 1.9x | 0.68x | 8.28x | 13.37x | 699M | ||
| Average | 2.67% | 3.02% | 5.86x | 3.05x | 0.74x | 8.55x | 16.38x | 3.64B | |
| Weighted average by Cap. | 1.98% | 2.23% | 12.22x | 2.48x | 0.75x | 9.02x | 12.87x |
Select your edition
All financial news and data tailored to specific country editions
















